---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-042498"
form_type: "8-K"
ticker: null
cik: "0001556263"
company_name: "Syros Pharmaceuticals, Inc."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T23:02:43.273795+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Syros Pharmaceuticals to voluntarily delist from Nasdaq; CEO Quirk steps down, wind-down underway

## Summary
- Voluntary delisting from Nasdaq; Form 25 to be filed ~March 10, 2025, effective ~March 20; intends to file Form 15 to suspend SEC reporting.
- CEO Gerald Quirk steps down as CEO/President effective March 1; remains on Board as director and consultant.
- Directors Peter Wirth, Marsha Fanucci, Nancy Simonian resign from Board effective immediately; no disagreement.
- Matthew Foster appointed Chief Restructuring Officer effective March 1 to oversee wind-down.
- Wind-down triggered by Phase 3 trial (SELECT-MDS-1) failure and default under Oxford Finance loan; operating under Oxford-approved budget.

## SEC filing metadata
- accession: 0001193125-25-042498
- form_type: 8-K
- cik: 0001556263
- company_name: Syros Pharmaceuticals, Inc.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 3.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/d926755d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-042498
- JSON: https://secwatch.observer/filing/0001193125-25-042498.json
- Plain text: https://secwatch.observer/filing/0001193125-25-042498.txt

## Key facts
- Executive change
  Gerald Quirk departed as Chief Executive Officer and President at Syros Pharmaceuticals, Inc..
  - Action: cease to serve
  - Role: Chief Executive Officer and President
  source text: Effective March 1, 2025, Gerald Quirk will cease to serve as Chief Executive Officer and President of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm
- Executive change
  Marsha H. Fanucci resigned as Director at Syros Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 28, 2025, each of Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., notified the Board of such director’s resignation from the Board and all committees or subcommittees thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm
- Executive change
  Nancy Simonian resigned as Director at Syros Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 28, 2025, each of Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., notified the Board of such director’s resignation from the Board and all committees or subcommittees thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm
- Executive change
  Peter Wirth resigned as Director at Syros Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 28, 2025, each of Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., notified the Board of such director’s resignation from the Board and all committees or subcommittees thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm
- Executive change
  Gerald Quirk was appointed as Director at Syros Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 28, 2025, Gerald Quirk was appointed to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1556263/000119312525042498/0001193125-25-042498-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.